In vitro Immunoassays
Perform initial screening tests using InnoSer’s in vitro immunoassays to select your lead candidate compounds and progress to in vivo studies with confidence
In vitro immunoassays function as a critical tool to study various aspects of the complex immune system in the context of health and disease. Human and rodent immune cell lines and primary cells allow to evaluate the effect of investigational compounds on immune cell composition, activation status and polarisation, give a clear view on mechanisms of action, allow the identification of key biomarkers and allow early identification of potential immune toxicity.
InnoSer offers preclinical research services using a wide range of commercially available cell lines and primary rodent (splenocytes, PBMCs) and human immune cell (T cells, B cells, macrophages, monocytes, PBMCs etc.,). Immunoassays using rodent or human cell lines are efficient, relatively inexpensive, have fast turn-around times, while primary cells allow to generate translational data taking into account disease mechanisms and patient variability. InnoSer’s immunoassay capabilities include macrophage polarization, T-cell activation and proliferation assays, cytokine release assays, tumor-killing assays, and mixed lymphocyte reaction assays. These examples listed can be used prior to or in conjunction with running in vivo studies in InnoSer’s mouse models of inflammatory and/or autoimmune diseases or our portfolio of immune-oncology rodent models.
Developing new, safe and efficacious therapies is an extremely intricate process. As a preclinical immunology contract research organisation (CRO), InnoSer partners with you to help you navigate the complexities of this research area.
Take advantage of InnoSer’s collaborative approach to develop the most optimal study design. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical immunology studies to InnoSer, you gain access to our in vitro and in vivo immunology drug development portfolio.
Services with in vitro immunology assays that InnoSer offers:
- Wide range of 2D or 3D in vitro immunology assays in (co-)cultures or organ-on-chip platforms in both rodent human primary (PBMC-derived) or immortalized rodent and human cell lines.
- Wide range of assays (macrophage polarisation, T cell, B cell activation assays, immuno-oncology, cell therapy tumor killing assays etc.,)
- Complementary immuno-oncology, inflammatory or autoimmune disease in vivo mouse models and in vivo PK/PD profiling services.
Key immunology assays that InnoSer offers:
- T-cell, B-cell and dendritic cell activation and proliferation assays
- LPS-induced inflammation assays
- Cytokine release assays
- Phagocytosis assays
- Immuno-oncology and tumor killing assays
- Macrophage polarization assays
- Mixed lymphocyte assays
- Immunotoxicity assays
- Biomarker and cell signaling analyses (flow cytometry, MSD, ELISA, qPCR, Western blot
Example data featuring in vitro immunology assays:
Macrophage polarization can be studied in vitro to evaluate the mechanism of action (MoA) of novel immunotherapies.
Effect of PI3K inhibition (LY294002) and MEK1/2 inhibition (Trametinib) on polarisation of M1 macrophages: HLA-DR expression shown as percentage (%) and (B) mean fluorescence intensity (MFI). Effect of PI3K inhibition (LY294002) and MEK1/2 inhibition (Trametinib) on viability of macrophages showing Trametinib-induced immunotoxicity of M1 cells (C).
Macrophage polarization can be studied in vitro to evaluate the mechanism of action (MoA) of novel immunotherapies.
Effect of PI3K inhibition (LY294002) and MEK1/2 inhibition (Trametinib) on polarization of M1 macrophages: HLA-DR expression shown as mean fluorescence intensity (MFI).
Macrophage polarization can be studied in vitro to evaluate the mechanism of action (MoA) of novel immunotherapies.
Effect of PI3K inhibition (LY294002) and MEK1/2 inhibition (Trametinib) on viability of macrophages showing Trametinib-induced immunotoxicity of M1 cells.
Related model options
Immunology Models Overview
Perform initial screening tests using InnoSer’s in vitro immunoassays to select your lead candidate compounds and progress to in vivo studies with confidence.
DTH Mouse Model
Evaluate your compound’s immunomodulatory or immunosuppressive potential in the delayed-type hypersensitivity (DTH) mouse model.
IL-23 Induced Psoriasis Mouse Model
Perform quick efficacy tests to evaluate your novel psoriasis treatment strategies using the acute IL-23-Induced Psoriasis Mouse model.
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.